April 13, 2022
The Multiple Myeloma Hub, run by Scientific Education Support (SES) in partnership with the European School of Haematology (ESH), is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in multiple myeloma (MM). The Multiple Myeloma Hub has continued to promote significant developments in the treatment and research of MM throughout Q1 of 2022.
The Multiple Myeloma Hub covered two key conferences in Q1 of this year, ensuring the MM community receive the latest news and insights in MM treatment and research. In February, the hub virtually attended the 4th European CAR T-cell Meeting, providing live social media coverage of the conference, as well as articles summarizing key presentations. The hub also virtually attended the 48th Annual Meeting of the EBMT, providing live coverage, expert interviews, and summary articles. The coverage provided for these congresses helped generate over 65,000 page views for the hub in Q1 and generated over 129,000 impressions on the social channels.
Reviewing the Multiple Myeloma Hub’s impact this quarter, Marta Llobet Canela, Multiple Myeloma Content Lead at Scientific Education Support, said:
“This quarter has been an especially busy period for the Multiple Myeloma Hub. As part of our commitment to continuously enhance the hub’s user experience, we introduced new digital innovations, including article learning objectives and interactive quizzes that test a user’s pre- and post-knowledge when reading an article. We have also updated the hub with Google Translate, and as a result, the hub’s content can now be translated into 100 different languages, which will further enhance our global coverage and help us reach new audiences.
“By attending key congresses and providing extensive coverage, we bring education to those who cannot attend and ensure that they are able to have sight of educational messages and vital updates in MM.
“Activity such as this would not be possible without our supporters. We would like to take this opportunity to show our gratitude to our existing supporters—Pfizer, Sanofi, AbbVie, Bristol Myers Squibb, Genentech, Roche, Amgen, Oncopeptides, Takeda, and Karyopharm Therapeutics. We would also like to thank our steering committee for their continued guidance and support.”
For more information on the Multiple Myeloma Hub, please visit multiplemyelomahub.com.
NOTES TO EDITOR
About multiple myeloma (MM)
Multiple myeloma (MM) is a form of blood cancer that begins with aberrant plasma cells—a type of white blood cell—in the bone marrow. It's called MM as it frequently affects several bones in the body, including the spine, skull, pelvis, and ribs, preventing the bone marrow from producing enough healthy blood cells while damaging and weakening the affected bones. MM accounts for 15% of all blood malignancies and 2% of all cancers.
About the Multiple Myeloma Hub
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MM. Our aim is to enhance knowledge of MM through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
The Multiple Myeloma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the Multiple Myeloma Hub supports HCPs worldwide.
Founded in partnership with the European School of Haematology (ESH) in 2017, the Multiple Myeloma Hub is guided by an international steering committee of experts in the field of MM. The steering committee meet regularly to discuss the performance of the Multiple Myeloma Hub and to devise action plans on how best to support the MM community and address any unmet educational needs.
Multiple Myeloma Hub supporters
Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.
If you are interested in becoming a Multiple Myeloma Hub supporter, please contact email@example.com.
About Scientific Education Support (SES)
SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.
Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology: the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, MDS Hub, and MPN Hub.
About the European School of Haematology (ESH)
The European School of Haematology (ESH) is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in haematology.
Looking to receive the latest news, project updates, and new offerings?